IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab No decrease in serum albumin below baseline or increase ...
Immunovant, Inc. IMVT announced positive initial data from the 600 mg multiple-ascending dose (MAD) portion of its early-stage study on its new pipeline candidate, IMVT-1402. The phase I study is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results